New Zealand markets close in 1 hour 22 minutes

BIIB Jan 2023 390.000 call

OPR - OPR Delayed price. Currency in USD
Add to watchlist
1.65000.0000 (0.00%)
As of 10:32AM EST. Market open.
Full screen
Previous close1.6500
Open1.9500
Bid0.0000
Ask0.7000
Strike390.00
Expiry date2023-01-20
Day's range1.6500 - 1.9500
Contract rangeN/A
Volume5
Open interest116
  • Motley Fool

    Why 2023 Could Be a Big Year for Biogen

    Biogen (NASDAQ: BIIB) is a business that generates more than $10 billion in revenue each year, with its multiple sclerosis treatments bringing in the bulk of its sales. With the company's sales declining in recent years, Biogen needs a catalyst to turn things around and help inject some bullishness behind the business, and having an effective treatment for Alzheimer's could play a huge role in that objective. Next year could prove to be a pivotal one for Biogen as investors can finally get some much-needed answers about whether lecanemab, a promising Alzheimer's treatment, could be the game changer the healthcare company is hoping that it will be for the business.

  • Zacks

    Biogen (BIIB), Sage Finish Zuranolone NDA Filing for Depression

    Biogen (BIIB) and Sage Therapeutics (SAGE) NDA submission for zuranolone for treating MDD and PPD is based on data from two late-stage studies, LANDSCAPE and NEST.

  • Zacks

    3 Biotech Stocks Aiming to Reinvent Mental Health Treatment

    Atai, Biogen, and Sage are working to develop new treatments for mental illness.